Prota/MCRI completes enrolment of Phase 2b multicentre clinical trial of probiotic oral immunotherapy for the treatment of peanut allergy (PPOIT-003) Media ReleaseSanice EmbletonMay 23, 2018Prota Therapeutics, Paul Kelly
Biomedical Translation Fund invests in further development of total artificial heart device Media ReleaseSanice EmbletonMay 17, 2018BiVACOR, Paul Kelly, OneVentures
Prota Therapeutics partners with world leading bioscience company, Chr. Hansen Media ReleaseSanice EmbletonApril 19, 2018Paul Kelly, Prota Therapeutics, OneVentures
OneVentures’ Investee Smart Sparrow Secures Strategic Investment from Global Education Leader Media ReleaseSanice EmbletonFebruary 5, 2018Smart Sparrow, Michelle Deaker, Grant Chamberlain
Find-me appoints Rachel Boden as new CEO Media ReleaseSanice EmbletonFebruary 5, 2018Find-Me Technologies, Anne-Marie Birkill
Citadel Group aquires OneVentures portfolio company Charm Health Media ReleaseSanice EmbletonSeptember 4, 2017Anne-Marie Birkill, Charm Health
OneVentures Boosts Healthcare Team Media ReleaseSanice EmbletonMay 29, 2017OneVentures, Paul Kelly, Anne-Marie Birkill, Michelle Deaker
OneVentures makes first investment for the Biomedical Translation Fund Media ReleaseSanice EmbletonMay 27, 2017Prota Therapeutics, Anne-Marie Birkill, Paul Kelly, Michelle Deaker
Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy Media ReleaseSanice EmbletonApril 7, 2017Prota Therapeutics, Paul Kelly
Find-Me Technologies Strengthens the Board in Readiness for Rapid Growth Media Release, AnnouncementSanice EmbletonFebruary 20, 2017Find-Me Technologies, Anne-Marie Birkill
OneVentures awarded Biomedical Translation $170M Funding Announcement, Media ReleaseSanice EmbletonDecember 14, 2016OneVentures, Paul Kelly
Clinical Genomics Strenghtens it's Leadership Team with Multiple Key Appointments Media ReleaseSanice EmbletonOctober 19, 2016Clinical Genomics, Paul Kelly
Data published in Cancer Medicine Demostrate Clinical Genomics' Blood Test for Colorectal Cancer Recurrence is Two-Fold More Sensitive than CEA Test Media ReleaseSanice EmbletonOctober 19, 2016Clinical Genomics, Paul Kelly
OneVentures appoints Dr Graeme Wald to life sciences investment team Media ReleaseSanice EmbletonAugust 31, 2016OneVentures, Paul Kelly, Anne-Marie Birkill, Michelle Deaker
DoseMe partners with Charm Health to improve management of high risk oncology medicines and deliver “precision medicine” to Australian cancer patients Media ReleaseSanice EmbletonJuly 18, 2016Anne-Marie Birkill, Charm Health
Icon Group signs up Charm Health to support cancer care Media ReleaseSanice EmbletonApril 19, 2016Anne-Marie Birkill, Charm Health
Thinking beyond the ideas boom: What Australia really needs is later stage capital and experience Media ReleaseSanice EmbletonMarch 10, 2016Michelle Deaker, OneVentures
OneVentures’ Innovation and Growth Fund II hits $100 million in FUM Media ReleaseSanice EmbletonDecember 17, 2015Michelle Deaker, Anne-Marie Birkill, Paul Kelly, OneVentures
OneVentures commits $3M to launch Australian wearable technology innovation for global dementia market Media ReleaseSanice EmbletonDecember 15, 2015Anne-Marie Birkill, OneVentures
Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S. Media ReleaseSanice EmbletonMarch 26, 2015Hatchtech
